D&C or Hysteroscopy Denied by Insurance? How to Appeal Abnormal Uterine Bleeding Coverage

Dilation and curettage (D&C) and hysteroscopy are common gynecological procedures performed to evaluate and treat abnormal uterine bleeding (AUB), remove polyps or fibroids, and investigate abnormal endometrial findings. Despite being well-established diagnostic and therapeutic procedures, they are frequently denied by insurance companies on grounds of insufficient diagnostic workup, premature intervention, or coding issues. Here's how to fight back.

Why D&C and Hysteroscopy Claims Get Denied

Endometrial biopsy not performed first. Many insurers require an in-office endometrial biopsy (EMB) — typically via Pipelle or similar device — before approving a surgical procedure for abnormal uterine bleeding. The endometrial biopsy serves as a first-line tissue sampling tool that is less invasive and less expensive than surgical hysteroscopy. If the biopsy was skipped or was technically inadequate (insufficient sample), the insurer may deny the surgical procedure.

Ultrasound findings not meeting criteria. A transvaginal ultrasound is usually the first imaging study for AUB. Insurers look for specific findings that support the need for a surgical procedure, such as:

• Endometrial stripe thickness >4mm in a postmenopausal woman
• Endometrial polyp visible on saline-infused sonogram (sonohysterogram)
• Submucosal fibroid distorting the uterine cavity
• Heterogeneous endometrium suggesting possible pathology

If the ultrasound was normal or inconclusive, the insurer may argue that surgical evaluation isn't yet justified.

Medical management not attempted. For premenopausal women with AUB due to anovulatory cycles (AUB-O) or structural causes (fibroids), insurers often expect trials of medical management — hormonal contraceptives, levonorgestrel IUD, tranexamic acid, or NSAIDs — before approving surgical intervention.

Insufficient documentation of bleeding severity. Insurers want to see that the bleeding is clinically significant: documentation of heavy menstrual bleeding (menorrhagia) causing anemia, social limitations, or quality-of-life impairment. Quantitative measures such as PBAC (Pictorial Blood Assessment Chart) scores or documentation of pad counts and anemia on CBC are helpful.

Coding and ICD-10 diagnosis issues. D&C and hysteroscopy are coded differently based on indication (diagnostic vs. operative, with vs. without biopsy, with polypectomy, etc.). An incorrect or unspecific ICD-10 diagnosis code can result in an automatic denial. This is particularly common when the procedure is coded as "abnormal uterine bleeding NOS" without a more specific underlying diagnosis.

Polyp removal vs. diagnostic procedure distinction. When hysteroscopy is performed to remove a polyp or fibroid (operative hysteroscopy), the coverage rules may differ from a diagnostic hysteroscopy with biopsy. Some plans require separate authorization for operative components.

D&C for incomplete miscarriage or pregnancy loss. For patients experiencing pregnancy loss, D&C coverage depends on plan type and how the claim is coded. Complications of pregnancy — including incomplete abortion or missed abortion — should be clearly documented with an appropriate ICD-10 code (such as O02.1 or O03.x) to ensure coverage under maternity or medical benefits.

What Evidence Supports Your Claim

The American College of Obstetricians and Gynecologists (ACOG) recommends hysteroscopy as the gold standard for evaluating intracavitary pathology (polyps, fibroids, synechiae) in women with AUB when other evaluations are inconclusive or have identified lesions needing treatment. Saline infusion sonography and hysteroscopy are complementary tools — both recognized in ACOG guidelines.

Building Your Appeal

Compile the complete workup record. Include transvaginal ultrasound reports (especially any sonohysterogram), CBC showing anemia if present, endometrial biopsy results if performed, and notes from every office visit documenting bleeding history and severity.

Get a letter from your gynecologist. The letter should describe: the clinical presentation (bleeding pattern, duration, severity), imaging findings, any prior biopsy results, medical treatments tried and their outcomes, and why hysteroscopy or D&C is the appropriate next step given your specific clinical picture.

Document medical management failure if applicable. If you tried hormonal therapy, IUDs, or medications and they didn't work, provide pharmacy records and office notes documenting these trials and their inadequate results.

Challenge inadequate biopsy arguments. If a prior endometrial biopsy was attempted but yielded insufficient tissue (common in older patients with stenotic cervices), the gynecologist's note documenting this failure supports proceeding to hysteroscopy.

Address postmenopausal bleeding separately. For postmenopausal women, any uterine bleeding requires endometrial evaluation. The clinical urgency of ruling out endometrial cancer supports prompt evaluation with hysteroscopy, which should be explicit in the appeal.

After an Internal Denial

Request external independent review by a gynecologist. Denials for hysteroscopy in the setting of AUB with documented imaging pathology or inadequate EMB are frequently overturned.

Fight Back With ClaimBack

Abnormal bleeding is distressing — and getting coverage for the procedure that can resolve it shouldn't require this much effort. ClaimBack helps you build the complete, clinically grounded appeal your insurer needs to reverse the decision.

Start your appeal at ClaimBack

Related Reading

• What Is Medical Necessity?
• How to Write an Insurance Appeal Letter
• Common Reasons Insurance Claims Are Denied